US2010256062A1PendingUtilityA1

Allelic Variants of Human Factor VIII

43
Individually held — no corporate assignee on recordPriority: Dec 6, 2004Filed: Dec 6, 2005Published: Oct 7, 2010
Est. expiryDec 6, 2024(expired)· nominal 20-yr term from priority
Inventors:Tommy E. HowardVincent La Terza
A61P 7/04C12Q 2600/158C12Q 2600/106C12Q 2600/172C12Q 2600/156A61K 38/37C07K 14/755C12Q 1/6883
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compositions and methods related to Factor VIII.

Claims

exact text as granted — not AI-modified
1 - 81 . (canceled) 
     
     
         82 . A purified FVIII having a haplotype selected from the group consisting of the H3 haplotype, H4 haplotype, H5 haplotype, and H6 haplotype. 
     
     
         83 . The FVIII of  claim 82  having the H4 haplotype. 
     
     
         84 . The FVIII of  claim 82  having the H5 haplotype. 
     
     
         85 . The FVIII of  claim 82  having the H6 haplotype. 
     
     
         86 - 92 . (canceled) 
     
     
         93 . The FVIII of  claim 82  having the H3 haplotype. 
     
     
         94 . The FVIII of  claim 82  with instructions for administration to a person who has been haplotyped with the same haplotype as the recombinant FVIII. 
     
     
         95 . The FVIII of  claim 82  having the H3 haplotype with instructions for administration to an African American hemophiliac. 
     
     
         96 . The FVIII of  claim 82  having the H4 haplotype with instructions for administration to an African American hemophiliac. 
     
     
         97 . The FVIII of  claim 82  having the H5 haplotype with instructions for administration to an African American hemophiliac. 
     
     
         98 . The FVIII of  claim 82  having the H6 haplotype with instructions for administration to a non African American hemophiliac. 
     
     
         99 . The FVIII of  claim 82  having the H6 haplotype with instructions for administration to a Chinese hemophiliac. 
     
     
         100 . A method for treating a hemophiliac comprising administering to the hemophiliac an effective amount of purified FVIII having a haplotype selected from the group consisting of the H3 haplotype, H4 haplotype, H5 haplotype, and H6 haplotype. 
     
     
         101 . The method of  claim 100 , wherein the recombinant FVIII has the H3 haplotype. 
     
     
         102 . The method of  claim 100 , wherein the FVIII has the H4 haplotype. 
     
     
         103 . The method of  claim 100 , wherein the recombinant FVIII has the H5 haplotype. 
     
     
         104 . The method of  claim 100 , wherein the FVIII has the H6 haplotype.

Join the waitlist — get patent alerts

Track US2010256062A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.